证券代码：002004 证券简称：华邦健康 编号：20210908 | --- | --- | --- | --- | --- | --- | |-------------------|-------------------------------|----------------------------------------------------|-------|---------------|------------------------------------------------------------| | | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | | 别 | 新闻发布会 | 路演活动 | | | | | | 现场参观 | | | | | | | 其他 | | | | | | 参与单位 名称及人 | | | | | 西南证券杜向阳、阮雯，交银基金黄鼎、朱亦宁、周中、范煜 | | 员姓名 | | | | | | | 时间 2021 | 年 9 月 8 日 | 10:00-11:00 | | ...

证券代码：002004 证券简称：华邦健康 编号：20210831 | --- | --- | --- | |------------|---------------------------|------------------------------------------------------------| | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | 系活动类 | 媒体采访 | 业绩说明会 | | 别 | 新闻发布会 | 路演活动 | | | 现场参观 | | | | 其他 | | | 参与单位 | | 西南证券杜向阳、阮雯，西南证投部张锴，长盛基金张伟光，新华 | | 名称及人 | | 基金张霖，国开证券周成娟，国都自营王义，博永投资陈亮，汇盛 | | 员姓名 | 建投梁露，穿石投资王俊 | | | 时间 2021 | 年 8 月 31 日 | 13:30-14:00 | | 地点 | 电话会议（西南证券组织） | | | 上市公司 | 董事兼总经理：张海安 | | | 接待人员 | 董事兼董事会秘书：彭云辉 | | | 姓名 | 董事会办公室主任：胡菁菁 | | | | ...

证券代码：002004 证券简称：华邦健康 编号：20210906 | --- | --- | --- | --- | --- | |------------|-------------------------------|------------------------------------------------------------|------------------------|------------------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中银证券邓周宇、周海涛，上银基金卢扬，中国人寿张树声，远惟 | | | | 名称及人 | | 投资张翠双，鼎晖投资彦婕，安信基金徐衍鹏，惠正投资易建军， | | | | 员姓名 | 阳来军 | 中国人保资管田垒，顺沣资产邓永明，百毅资本闫小龙，大成基金 | | | | | | | | | | 时间 2021 | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20210929 | --- | --- | --- | --- | --- | |-------------|------------------------------------|--------------------------------------------------------------|-------|--------------------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中金公司张一弛、李千翊，趣时资产王晓东，东方红资产杨仁眉、 | | | | 名称及人 | | 孙梦瑶，上投摩根蔡云翔，高毅资产刘慧敏，景领投资张轶伦，德 | | | | 员姓名 | 福资本裴彦春，德瑞恒丰何小华、方清 | | | | | 时间 | 2021 年 9 月 29 ...

证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211122 | --- | --- | --- | --- | --- | |---------------|---------------------------------|--------------------------------------------------------|------------------|----------------------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 东吴基金、鑫元基金、博煊资产、沣京资本 | | | | 名称及人 | | | | | | 员姓名 | | | | | | 时间 2021 | 年 11 月 22 日 | 16:00-16:40 | | | | 地点 电话会议 | | | | | | | | | | | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211209 | --- | --- | --- | --- | --- | |---------------|----------------------------------|---------------------------------------|-----------------------------------------------------------------------------------------------------------------------|----------------------| | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 其他（线上电话会议） | | | | | 参与单位 | | | 中银证券、交银施罗德基金、建信基金、富国基金、华夏久盈、华 | | | 名称及人 | 宝信托 | | | | | 员姓名 ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211101 | --- | --- | --- | --- | --- | |-------------------|-------------------------------------|------------------------------------------------------------|----------------------------|-------| | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | 别 | 新闻发布会 | 路演活动 | | | | | 现场参观 | | | | | | 其他 | | | | | 参与单位 | | 中银证券邓周宇、杨志威、梁端玉，交银施罗德基金、重阳投资胡 | | | | 名称及人 | | 敏、兴业基金代鹏举、尚石投资贾鹏飞、德睿恒丰江昕、合正普惠 | | | | 员姓名 | | 投资原芳、南银理财钱晟、汇华理财张昕 | | | | 时间 20 ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20211129 | --- | --- | --- | --- | --- | --- | --- | |----------|------------------------------------------------|----------------------------------------|-------------------------|-------|---------------------------------------------------------------|-------| | | | | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | | | | 系活动类 | 媒体采访 | 业绩说明会 | | | | | | 别 | 新闻发布会 | 路演活动 | | | | | | | 现场参观 | | | | | | | | 其他（线上电话会议） | | | | | | | 参与单位 | | 线下调研：中信证券、银河证券、淳阳基金 | | | | | ...

1 证券代码：002004 证券简称：华邦健康 华邦生命健康股份有限公司投资者关系活动记录表 编号：20220107 | --- | --- | --- | --- | |------------|--------------------------------------------------------------|---------------------------------------------------------|-------| | | | | | | 投资者关 | 特定对象调研 | 分析师会议 | | | 系活动类 | 媒体采访 | 业绩说明会 | | | 别 | 新闻发布会 | 路演活动 | | | | 现场参观 | | | | | 其他（线上电话会议） | | | | 参与单位 | 工银瑞信基金 | | | | 名称及人 | | | | | 员姓名 | | | | | 时间 2022 | 年 1 月 7 日 | 9:30-12:00 | | | | 地点 公司会议室、重庆北部宽仁医院 | | | | 上市公司 | 董事、董事会秘书：彭云辉 | | | | 接待人员 | 投资者关系 ...

Financial Performance - The company's revenue for Q3 2022 reached ¥3,481,328,298.92, representing a 20.80% increase year-over-year[4] - Net profit attributable to shareholders decreased by 6.21% to ¥157,107,051.58 for the quarter, while year-to-date net profit increased by 37.73% to ¥717,022,611.56[4] - The net profit for the current period reached ¥1,342,581,873.08, a significant increase from ¥715,999,282.39 in the previous period, representing an increase of approximately 87.2%[28] - Operating profit for the current period was ¥1,818,006,436.61, compared to ¥923,649,475.63 in the previous period, indicating an increase of about 96.8%[28] - Total operating revenue for the current period reached ¥10,180,991,733.93, an increase of 17.98% compared to ¥8,629,345,347.58 in the previous period[25] - The company reported a total comprehensive income of ¥1,553,326,463.12, compared to ¥721,527,099.20 in the previous period, which is an increase of approximately 115.5%[28] - Earnings per share (EPS) for the current period was ¥0.3621, up from ¥0.2629 in the previous period, representing an increase of about 37.8%[28] Cash Flow and Investments - The net cash flow from operating activities for the year-to-date period was ¥1,888,672,141.44, showing a significant increase of 136.41% compared to the previous year[4] - Cash flow from operating activities generated a net amount of ¥1,888,672,141.44, compared to ¥798,903,991.74 in the previous period, marking an increase of about 136.4%[31] - The cash inflow from investment activities totaled ¥6,399,652,310.89, compared to ¥5,983,905,914.21 in the previous period, indicating an increase of approximately 6.9%[31] - The company’s cash outflow from investment activities was ¥6,423,466,215.24, slightly higher than ¥6,166,690,319.17 in the previous period, reflecting an increase of about 4.2%[31] - The net increase in cash and cash equivalents was $1,017,905,834.60, significantly higher than $427,130,522.60 previously[34] - The ending balance of cash and cash equivalents reached $3,520,862,118.20, up from $2,643,608,645.75[34] Assets and Liabilities - The total assets of the company as of the end of the reporting period were ¥30,852,486,707.32, reflecting a 2.69% increase from the end of the previous year[7] - Total assets increased to ¥30,852,486,707.32, compared to ¥30,044,426,750.47 in the previous period, marking a growth of 2.68%[24] - Total liabilities decreased slightly to ¥14,059,741,767.02 from ¥14,220,677,628.50, a reduction of 1.13%[24] - The equity attributable to shareholders of the parent company rose to ¥10,476,928,031.26, up from ¥10,109,391,327.10, indicating a growth of 3.63%[24] Shareholder Information - The total number of common shareholders at the end of the reporting period is 87,819, with the largest shareholder, Tibet Huibang Technology Co., Ltd., holding 18.71% of shares[13] - The total number of shares held by the top ten shareholders includes 370,449,804 shares held by Tibet Huibang Technology Co., Ltd., which is the only shareholder with over 10% ownership[13] - The company has a total of 30 million shares held by Jiang Xueping, with no shares pledged[17] Operational Metrics - Total operating costs amounted to ¥8,815,184,892.05, up 10.31% from ¥7,993,861,821.86 in the prior period[25] - Research and development expenses increased to ¥286,550,552.75, reflecting a rise of 29.15% from ¥221,884,196.23 year-over-year[25] - The company experienced a significant increase in accounts receivable, which rose by 95.05% to ¥186,284,511.53, mainly due to an increase in bank acceptance bills received during the reporting period[9] - The company reported trading financial assets of approximately ¥753.37 million, down from ¥1.03 billion, representing a decrease of about 27%[18] Strategic Outlook - The company has not disclosed any new product developments or market expansion strategies in the current report[20] - There are no significant mergers or acquisitions reported in the current quarter[20] - The company is focusing on expanding its market presence and enhancing product offerings, although specific new products or technologies were not detailed in the report[27] - The company plans to continue expanding its market presence and investing in new technologies to drive future growth[28]